Azora Therapeutics Reports $64.6 Million Q3 Net Loss and $22.0 Million in Cash

Azora Therapeutics reported a third-quarter 2026 net loss of $64.6 million, including a $57.1 million noncash charge related to milestone warrant rights. Cash and cash equivalents totaled $22.0 million at September 30, 2026. The company said its current cash is expected to fund its operating plan…